Category Archives: Business and Investments

Latest From Business and Investments

The Good, the Bad, and the Ugly for Biotech IPOs

2012-11-12-Technology-vs-HC-IPOs-btn

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

It Takes a Village: The New Pharma-VC Model for Biotech Investing

bif-hall

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BayBio Op-ed featured in Xconomy

GM

Gail Maderis, President & CEO of BayBio, recently discussed the strength of Northern California’s biotechnology industry and the BIO Investor Forum in Xconomy: With more than 850 biotechnology companies, the Bay Area is the oldest, largest and most productive life sciences cluster in the world, employing more than 125,000 people in the region. For more than 30 years, this region has led the world in researching and delivering new cures and treatments for debilitating diseases Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of certainty for public exits, subsequent private financings, and even pharma licensing deals are over. IPOs have been out of favor for five years, venture firms are turning away from the sector, and fewer licensing deals are being cut. What is less understood about this uncertain environment is how it has forced management and their venture backers, to not only rethink Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Kinase Drug Development – Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last decade, but when we take a look at recent approvals and NDA filings there seems to be a strengthening of the field. There are now 16 kinase inhibitors that have been approved and five seeking regulatory approval in the next few months. The last two years in particular has been a boom for the KIs, with seven approvals, three of which target Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,